Andere Kunden interessierten sich auch für
![Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance]( "Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance")
Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance115,99 €![Neuroendocrine Perspectives]( "Neuroendocrine Perspectives")
Neuroendocrine Perspectives77,99 €![Neuroendocrine Perspectives]( "Neuroendocrine Perspectives")
Neuroendocrine Perspectives39,99 €![Molecular Pathology in Clinical Practice: Oncology]( "Molecular Pathology in Clinical Practice: Oncology")
Molecular Pathology in Clinical Practice: Oncology91,99 €![Textbook of Energy Balance, Neuropeptide Hormones, and Neuroendocrine Function]( "Textbook of Energy Balance, Neuropeptide Hormones, and Neuroendocrine Function")
Textbook of Energy Balance, Neuropeptide Hormones, and Neuroendocrine Function100,99 €![Neuroendocrine Tumors]( "Neuroendocrine Tumors")
Neuroendocrine Tumors113,99 €![Oncologic Breast Surgery]( "Oncologic Breast Surgery")
Oncologic Breast Surgery121,99 €
The book describes the ability of a series of endocrine-derived compounds,
i.e. CHRH, LHRH, somatostatin, anti-androgens, and aromatase inhibitors to
exert a direct anti-neoplastic activity or to potentiate the activity of
traditional chemotherapeutic agents on neuroendocrine and solid tumors. In
addition, a new class of potent GH-releasers, GSHs/Ghrelin, endowed with
important endocrine and extra-endcocrine action, is presented. Therefore,
in addition to traditional chemotherapy, characterized by high toxicity and
non-selective action on tumoral cells, the reader can find a new approach
with more selective, less cytotoxic endocrine derived compounds TOC:
LHRH/Somatostatin.- Chapter1 Twenty-five Years of Endocrine Oncology with Analogs of Hypothalamic Peptides: an Overview.- Chapter2 Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma.- Chapter3 Luteinizing Hormone-releasing Hormone Antagonists in Gynecology.- Chapter4 Physiology and Pharmacology of Somatostatin and Its Receptors.- Chapter5 Investigation of LHRH Receptor Involvement in Melanoma Growth and Progression.- Somatostatin/GHRH/GH.- Chapter6 Cortistatin: Not Simply a Natural Somatostatin Analogue.- Chapter7 Antineoplastic and Antiangiogenic Actions of Somatostatin Analogs.- Chapter8 Somatostatin in Clinical Endocrinology.- Chapter9 Antagonists of Growth Hormone-releasing Hormone in Oncology.- Chapter10 GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives.- Ghrelin and Ghrelin Mimetics (GHS).- Chapter11 Hypothalamic Circuits Responsive to Ghrelin: Regulation by Leptin and Insulin.- Chapter12 Physiological Function of Growth Hormone Secretagogue Receptors in the Cardiovascular System.- Chapter13 Endocrine and Extraendocrine Activity of Ghrelin and the GHS: Basic Research.- Chapter14 Endocrine and Nonendocrine Actions of Ghrelin and GHS: State of the Art in Clinical Research.- Hormonal Treatments for Endocrine-Dependent Tumors.- Chapter15 Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects.- Chapter16 Hormonal Treatment of Endocrine-Dependent Tumors: Clinical Considerations.- Chapter17 Letrozole in the Treatment of Advanced Breast Cancer.
i.e. CHRH, LHRH, somatostatin, anti-androgens, and aromatase inhibitors to
exert a direct anti-neoplastic activity or to potentiate the activity of
traditional chemotherapeutic agents on neuroendocrine and solid tumors. In
addition, a new class of potent GH-releasers, GSHs/Ghrelin, endowed with
important endocrine and extra-endcocrine action, is presented. Therefore,
in addition to traditional chemotherapy, characterized by high toxicity and
non-selective action on tumoral cells, the reader can find a new approach
with more selective, less cytotoxic endocrine derived compounds TOC:
LHRH/Somatostatin.- Chapter1 Twenty-five Years of Endocrine Oncology with Analogs of Hypothalamic Peptides: an Overview.- Chapter2 Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma.- Chapter3 Luteinizing Hormone-releasing Hormone Antagonists in Gynecology.- Chapter4 Physiology and Pharmacology of Somatostatin and Its Receptors.- Chapter5 Investigation of LHRH Receptor Involvement in Melanoma Growth and Progression.- Somatostatin/GHRH/GH.- Chapter6 Cortistatin: Not Simply a Natural Somatostatin Analogue.- Chapter7 Antineoplastic and Antiangiogenic Actions of Somatostatin Analogs.- Chapter8 Somatostatin in Clinical Endocrinology.- Chapter9 Antagonists of Growth Hormone-releasing Hormone in Oncology.- Chapter10 GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives.- Ghrelin and Ghrelin Mimetics (GHS).- Chapter11 Hypothalamic Circuits Responsive to Ghrelin: Regulation by Leptin and Insulin.- Chapter12 Physiological Function of Growth Hormone Secretagogue Receptors in the Cardiovascular System.- Chapter13 Endocrine and Extraendocrine Activity of Ghrelin and the GHS: Basic Research.- Chapter14 Endocrine and Nonendocrine Actions of Ghrelin and GHS: State of the Art in Clinical Research.- Hormonal Treatments for Endocrine-Dependent Tumors.- Chapter15 Hormonal Treatments of Endocrine-Dependent Tumors: Preclinical Aspects.- Chapter16 Hormonal Treatment of Endocrine-Dependent Tumors: Clinical Considerations.- Chapter17 Letrozole in the Treatment of Advanced Breast Cancer.